Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.63 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.55 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664654 | 0.98 | L3MBTL1 (0.65) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL12139779 | 0.93 | L3MBTL1 (0.56) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL1045855 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL8972823 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL4450061 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL8972813 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL8972980 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL7060548 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL768398 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A | |
| SCHEMBL9415758 | 0.87 | L3MBTL1 (0.80) | GNAI3GNAI1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | GNAI3 1942/4885GNAI1 2223/4885L3MBTL1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.